PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
Clinical trials for PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to fix chemo side effect that leaves cancer survivors at risk of bleeding
Disease control Recruiting nowThis study tests whether adding a vitamin A-like drug (ATRA) to a platelet-boosting medication (romiplostim N01) works better than the platelet drug alone for cancer survivors whose platelet counts stay low after chemotherapy. About 220 adults with gynecologic, breast, or lung ca…
Matched conditions: PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated May 16, 2026 23:37 UTC
-
New combo aims to fix chemo side effect in GI cancer survivors
Disease control Recruiting nowThis study looks at adults whose platelet counts stayed low after finishing chemotherapy for gastrointestinal cancers (like stomach, pancreas, or colorectal). Participants get either a standard platelet-boosting drug alone or combined with another medicine (ATRA) for 12 weeks. Th…
Matched conditions: PERSISTENT ISOLATED CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated May 15, 2026 11:57 UTC